SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of a syringe and medicine bottle with some broken glass
Manufacturing
Biotechs Secure Alternative Fill/Finish Capacity Amid Scrutiny of Novo Site
Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by quality problems at an ex-Catalent facility in Indiana. Novo Nordisk, meanwhile, has been tight-lipped about whether its own FDA applications have been affected.
December 2, 2025
 · 
6 min read
 · 
Nick Paul Taylor
Handshake of diplomats of Great Britain and United States, concept of agreement, cooperation. Flat vector stock illustration. Flags of countries on black background. Meeting of politicians
Drug pricing
UK Agrees To Boost Drug Spending by 25% To Avoid US Pharma Tariffs
U.K.-based pharmas will not face tariffs as long as Donald Trump is president, according to the agreement.
December 1, 2025
 · 
1 min read
 · 
Annalee Armstrong
Insulin syringe pens wrapped in dollar bills on a blue background. Pharmaceutical monopolists raise drug prices. Top view with copy space
Drug Delivery
Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program
Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug purchased through LillyDirect. Both pharmas recently struck a deal with the White House for cheaper prices via the yet-to-be-launched TrumpRx.
December 1, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
A piggy bank crammed with $100 bills on a background of American cash
Series B
Novartis-Backed Protego Eyes Pivotal Amyloidosis Study With $130M Series B
Protego Biopharma is advancing a small-molecule drug that helps light chain proteins fold correctly, in turn addressing the underlying biological cause of AL amyloidosis.
December 1, 2025
 · 
1 min read
 · 
Tristan Manalac
Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.
Gene editing
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD
The centerpiece of the deal is the in vivo editor TSRA-196, which in preclinical studies has shown robust editing at SERPINA1, the locus linked to alpha-1 antitrypsin deficiency.
December 1, 2025
 · 
1 min read
 · 
Tristan Manalac
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Vaccines
FDA’s Prasad Links 10 Child Deaths to COVID-19 Vaccines, Eyes Stricter Review Guidelines
The alleged deaths were detected by the FDA’s Vaccine Adverse Event Reporting System, reports from which “generally cannot be used to determine” causation or even contribution, according to the agency.
December 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Office worker, employee being late for work, looking untidy. Deadlines and time management. Contemporary art collage. Concept of business, office lifestyle, career, challenges
FDA
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
December 1, 2025
 · 
1 min read
 · 
Tristan Manalac
iStock, quantic69
PARTNERED WITH VIVA BIOTECH
Building the Next Generation of Biologics: Inside the Future of Protein Engineering
As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new bottleneck: engineering and producing molecules whose complexity challenges conventional workflows.
December 1, 2025
 · 
9 min read
 · 
BioSpace Insights
Businessmen helping their friend climbing the rock, teamwork, partnership in business concept
Cell Therapy
6 Companies Hanging On in Cell Therapy
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.
December 1, 2025
 · 
9 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS